

Special Issue

The Development of Novel Cancer Immunotherapies and Target Antigens

Message from the Guest Editors

A wide variety of solid tumors still lack an effective therapy. Unfortunately, complete surgical resection often fails to completely eliminate the tumor, leading to the recurrence of cancer and resistance to current therapies. This Special Issue aims to address new immunotherapy strategies along with a description of the immunological microenvironment of tumors, which are difficult to manage clinically. Advances in the design of new strategies against cancer such as immunotherapy, neoantigen vaccines and novel immunomodulators will be evaluated. Furthermore, new immunotherapy strategies may be key to improving current immune checkpoint blockade (ICB) therapies to allow for overcoming the barriers intrinsic to the tumor microenvironment and rethinking the next steps in the evolution of cancer immunotherapy.

Guest Editors

Dr. Ricardo Gargini

Department of Pathological Anatomy Hospital '12 de Octubre',
Biomedical Research Institute Hospital '12 de Octubre' IMAS12, Madrid,
Spain

Dr. Marina I. Garin

Biomedical Innovation Unit, CIEMAT/CIBERER/IIS Fundación Jiménez
Díaz, Madrid, Spain

Deadline for manuscript submissions

closed (1 January 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/192716

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).